News

Men with prostrate cancer on androgen deprivation therapy (ADT) experienced highly statistically significant increases in bone mineral density (BMD) after one year of treatment with Acapodene (toremifene citrate).

The recommendation is based on data presented from phase III clinical trials that evaluated the effects of the drug in 70,000 infants. The FDA will now consider the

The preliminary results showed that the vaccine was safe and well-tolerated in 300 healthy volunteers. A 30 microgram dose with an adjuvant in a two-dose regimen demonstrated an

The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of approximately $4.1 million, according to Glenmark. Pursuant to the

The submission is being made for satraplatin to be used in combination with prednisone as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer (HRPC). GCP Biotech

BGC20-0166 works by targeting two distinct mechanisms of serotonin signaling. BTG has advanced the compound from preclinical validation studies to the current clinical trial in less than eighteen

The recommendation is expected to be adopted by the European Commission in early 2006. EU orphan drug designation encourages the development of products to treat life-threatening or very

Factor VII is a natural protein with a pivotal role in blood coagulation and clotting. Uncontrolled bleeding is the most common cause of trauma mortality in the hospital

Protox plans to initiate phase I clinical trials of PRX302 early next year upon approval of the IND by the FDA. The trial is expected to enroll 18-24